I am a passionate entrepreneur working to discover and develop novel therapies for the treatment of cancer and other serious human diseases. Outside the office, I am an avid golfer, amatuer drummer, former decent baskeball player, happily married husband and proud father to four incredible kids.

Dallin M. Anderson serves as Chairman and President of Tolero Pharmaceuticals, a clinical stage drug develpoment company focused in hematology. In 2003, Mr. Anderson founded Montigen Pharmaceuticals, Inc., a privately held drug discovery and development company focused in oncology, where he served as Chairman, President, and CEO. Montigen was acquired by SuperGen (NASDAQ: SUPG), now Otsuka, in 2006, and Mr. Anderson subsequently served as Senior Vice President of Commercial Development at Supergen. Mr. Anderson’s work experience prior to Montigen includes roles at McKinsey & Company and Intel. Mr. Anderson was honored as a finalist for the Ernst & Young Entrepreneur of the Year award for the Utah/Colorado region, is a five-time inductee into the vSpring v100 Entrepreneurs, and was selected as one of Utah Business Magazine's Top 40 under 40. Mr. Anderson is active in mentoring entrepreneurs and business leaders across a range of industries, and serves on the board of various for profit and non profit organizations. Mr. Anderson received an AAS in Finance from Brigham Young University Idaho where he served as Student Body President and graduated with Highest Honors, and a BS in Accounting from Brigham Young University where he again served as Student body President and graduated with University Honors. Mr. Anderson received an MBA from Harvard Business School.